The International Psoriasis and Arthritis Research Team (IPART) is a highly successful, international consortium of rheumatologists and dermatologists across Canada and the United States with expertise in genomics, inflammation, immunology and epidemiology. IPART was formed in 2007 and spearheaded by Dr. Dafna D. Gladman, its Principal Investigator.  IPART was a recipient of the CIHR New Emerging Team (NET) grant over a period of five (5) years from July 2007 and ended in June 2012.  While IPART continued heavily on its genetics and biomarker research since the end of the CIHR – NET grant in 2012, it has evolved into a major engine for research in psoriasis and PsA, making significant advances in the field.

Number of Patients







Number of active collaborating sites, number of PsC patients, and number of PsA patients in the full IPART database as of March 31, 2022.

This program focuses on the biological basis of PsA and psoriasis with an emphasis on predicting onset and severity of PsA using clinical and genetic variables, and identification of disease biomarkers. The biologic basis for the interplay between the skin and joint manifestations in psoriasis has yet to be fully delineated. The overall goal underlying this research network is make advances that will lead to the significant improvement in outcomes for patients with psoriasis and PsA. IPART’s objectives are 1) to develop a database of cohorts of carefully phenotyped patients with psoriasis and PsA, 2) to identify susceptibility factors for PsA among patients with psoriasis, and 3) to identify risk factors for disease severity among patients with psoriasis and PsA using the database.